The Malignant Germ Cell International Consortium (MaGIC) was launched in 2009 when the Children’s Oncology Group (US) and the Children’s Cancer and Leukaemia Group (UK) signed a Memorandum of Understanding to combine data from seven clinical trials that were conducted between 1983-2009.
MaGIC’s first annual meeting took place in 2010 in Boston, Massachusetts.
In 2015, MaGIC published Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States, which derived from the MaGIC Data Commons. The revised risk classification, which includes both pediatric and adolescent patients, was developed to serve as the basis for future international collaborative trials. To date, MaGIC has opened one trial using the revised risk classification (AGCT1531) but has also influenced other open trials to revise their studies to allow for younger patient enrollment (AO31102 and AGCT1532).
MaGIC Timeline
12th MaGIC Annual Meeting, Indianapolis, Indiana
MaGIC Pathology Consensus Conference (Virtual)
11th MaGIC Annual Meeting (Virtual)
The Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and Dana-Farber Cancer Institute (DFCI) joins MaGIC
MaGIC officially joins the PCDC
10th MaGIC Annual Meeting (Cambridge UK)
International Extracranial Germ Cell Tumour Conference (Cambridge UK)
9th MaGIC Annual Meeting (Mumbai, India)
Children’s Oncology Group clinical trial AGCT1532 opens
8th MaGIC Annual Meeting (Atlanta, GA)
Children’s Oncology Group clinical trial AGCT1531 opens
7th MaGIC Annual Meeting (Cambridge, UK)
Société Française de Lutte contre les Cancers et Leucémies de l’Enfant et de l’Adolescent (France) joins MaGIC
6th MaGIC Annual Meeting (Cambridge, UK)
St Baldrick’s Foundation awards MaGIC multi-year funding
Alliance clinical trial A031102 (TIGER) opens
MaGIC Revised Risk Stratification published; derived from MaGIC Data Commons
5th MaGIC Annual Meeting (Boston, MA)
Brazilian Germ Cell Tumor Committee joins MaGIC
4th MaGIC Annual Meeting (Cambridge, UK)
3rd MaGIC Annual Meeting (Boston, MA)
Medical Research Council joins MaGIC
2nd MaGIC Annual Meeting (Cambridge, UK)
NRG Oncology joins MaGIC
1st MaGIC Annual Meeting (Boston, MA)
Children’s Oncology Group (US) and Children’s Cancer and Leukemia Group (UK) sign Memorandum of Understanding to combine data from 7 retrospective clinical trials